Jennifer Fulk
Sr. Dir., Global Financial Operations, Elanco
ELI LILLY & COMPANY
Jennifer Fulk is the Senior Director of Global Finance Operations at Elanco Animal Health, a division of Eli Lilly and Company. Prior to her current role, Jennifer was the Chief Financial Officer for Lilly Germany, Austria, and Switzerland. She has enjoyed over 9 years with Lilly.
Jennifer will be one of the distinguished speakers at the 7th Semi-Annual Life Science Financial Forum.
Why are the 6th & 7th Semi-Annual Life Science Financial Forums important to financial executives?
The life science environment is on a trajectory of even more complexity and economic pressures. This requires finance executives supporting companies in this place to be nimble and smart while maintaining proper controls and mitigating financial risks. There is no better way to sharpen thinking than stepping outside of your own company and learning from the experiences of others. The Semi-Annual Life Science Financial Forum is the opportunity to do just that – formally with a very thoughtful agenda, and informally through networking periods.
What initiatives are on the horizon at your organization for the financial department in 2015-2016?
Lilly bought Novartis Animal Health January 1, 2015. This results in a combination of two like-size billion dollar animal health businesses. All of our activities in finance are focused on this over the next couple of years. The key points are: maintaining current operations across both companies, ensuring accounting controls remain effective, the SAP implementation across the globe, and long term finance support planning.
